Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy

NATerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
HyperphenylalaninemiaPhenylketonuria
Interventions
DRUG

Sapropterin

20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BioMarin Pharmaceutical

INDUSTRY

lead

The University of Texas Health Science Center, Houston

OTHER